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Abstract
Background: Little evidence exists to comprehensively estimate adolescent viral suppression after initiation on
antiretroviral therapy in sub-Saharan Africa. This study examines adolescent progression along the HIV care cascade
to viral suppression for adolescents initiated on antiretroviral therapy in South Africa.
Methods: All adolescents ever initiated on antiretroviral therapy (n=1080) by 2015 in a health district of the Eastern
Cape, South Africa, were interviewed in 2014–2015. Clinical records were extracted from 52 healthcare facilities
through January 2018 (including records in multiple facilities). Mortality and loss to follow-up rates were corrected
for transfers. Predictors of progression through the HIV care cascade were tested using sequential multivariable
logistic regressions. Predicted probabilities for the effects of significant predictors were estimated by sex and mode
of infection.
Results: Corrected mortality and loss to follow-up rates were 3.3 and 16.9%, respectively. Among adolescents with
clinical records, 92.3% had ≥1 viral load, but only 51.1% of viral loads were from the past 12 months. Adolescents
on ART for ≥2 years (AOR 3.42 [95%CI 2.14–5.47], p< 0.001) and who experienced decentralised care (AOR 1.39
[95%CI 1.06–1.83], p=0.018) were more likely to have a recent viral load. The average effect of decentralised care on
recent viral load was greater for female (AOR 2.39 [95%CI 1.29–4.43], p=0.006) and sexually infected adolescents
(AOR 3.48 [95%CI 1.04–11.65], p=0.043). Of the total cohort, 47.5% were recorded as fully virally suppressed at most
recent test. Only 23.2% were recorded as fully virally suppressed within the past 12 months. Younger adolescents
(AOR 1.39 [95%CI 1.06–1.82], p=0.017) and those on ART for ≥2 years (AOR 1.70 [95%CI 1.12–2.58], p=0.013) were
more likely to be fully viral suppressed.
Conclusions: Viral load recording and viral suppression rates remain low for ART-initiated adolescents in South
Africa. Improved outcomes for this population require stronger engagement in care and viral load monitoring.
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Background
The expansion of access to antiretroviral therapy
(ART) has enabled more children vertically infected
with HIV to survive into adolescence [1]. In parallel,
the high rate of new HIV infections through sexual
transmission among youth has contributed to a grow-
ing population of adolescents living with HIV. Of the
estimated 2.1 million adolescents living with HIV, 85%
reside in sub-Saharan Africa [2, 3]. Concern about the
growing population of adolescents requiring lifelong
ART has drawn increasing global attention to the need
to better monitor this key population and to tailor
treatment services [1, 4].
Previous studies have demonstrated that, even on
treatment, adolescents exhibit the worst health outcomes
compared to all other age groups [2, 5]. In South Africa,
which houses the world’s largest ART programme, ado-
lescents have repeatedly demonstrated the lowest rates
of retention in care and viral suppression compared to
other age groups [6]. The HIV care cascade has been
widely used among various patient populations to iden-
tify progress at critical stages along the continuum of
care from HIV testing to ART initiation and viral sup-
pression [7]. This tool allows for both the monitoring of
patients’ health and identification of key gaps in care
that can be targeted by interventions in alignment with
the UNAIDS 90–90-90 treatment target for 2020 [8, 9].
Although progress along the HIV care cascade has
been well-documented globally for adults and adult key
populations, less evidence exists for adolescents living
with HIV [6, 7, 9]. A recent retrospective analysis of
individually linked records from South Africa’s National
Health Laboratory Service database estimated that 66%
of older adolescents (15–19 years old) had initiated ART
by 2016 [10]. While the study provides a robust estimate
for the second cascade step of ART initiation, it does
not extend analyses to evaluate rates of viral suppression
for the third target in the care cascade.
In South Africa, one systematic review of data from
youth living with HIV estimated that only 10% were virally
suppressed as of 2013, before implementation of universal
test and treat in 2016 [6]. However, the review estimated
viral suppression using rates reported for patients aged 9–
29, well beyond the window of adolescence [11]. Similarly,
the 2017 South African National HIV Prevalence, Inci-
dence, Behaviour, and Communication Survey estimated
viral suppression for youths aged 15–24, with no discrete
data for all adolescents aged 10–19 [12]. This lack of dis-
aggregated data for adolescents limits the applicability of
findings for this key population [4]. Furthermore, viral
suppression in the survey was calculated by active collec-
tion and testing of blood samples, not evaluation of clin-
ical records that would be available to healthcare
providers. Research is urgently required to understand the
current reality of adolescent HIV care progression to the
final cascade step of viral suppression in South Africa,
with data that reflects contexts beyond well-resourced
clinics or urban centres [13].
In this study, we evaluate the progression of ART-
initiated adolescents to viral suppression along the
HIV care cascade in South Africa, including oper-
ational outcomes as well as mortality and retention in
care, using data up to 2018 from multiple healthcare
facilities within South Africa’s decentralised public
healthcare system. In addition, we report associations
between stages of the cascade and adolescents’ socio-
demographic and treatment-related characteristics.
Methods
Participants and procedures
In this longitudinal cohort study, data were analysed
from clinical records and interviews with ART-
initiated adolescents in a health district of the Eastern
Cape, South Africa. The study setting was specifically
selected to reflect poverty and healthcare contexts
similar to other low-income Southern African con-
texts and included rural, peri-urban, and urban loca-
tions [14]. The province is characterised by high HIV
and TB burden, and significant challenges for this
province’s healthcare system include limited infra-
structure and human resource challenges [15]. Ado-
lescent participants were recruited from March 2014
through September 2015, as previously described [16].
All healthcare facilities within the health district that
provided ART to at least five adolescents were
included in the study (n=52, including eight hospital
wards, five community health centres, and 39 primary
care clinics). At each healthcare facility, patient regis-
ters were reviewed to identify all adolescents aged
10–19 years who had ever initiated ART, including
those who had defaulted in care or been lost to fol-
low up (LTFU). Adolescents identified through
clinical records were traced to >180 communities,
approached for study participation, and, if consenting,
interviewed at their preferred location.
Data collection
Clinical record review
At each of the 52 healthcare facilities, routine clinical
records were searched for every study participant, across
both paper-based and electronic records. This intensive
data collection approach enables the extraction of partic-
ipants’ records from all included facilities where they
may have received care, including undocumented silent
transfers to a new facility. Data were extracted in two
rounds using a standardized form, covering records from
2014 to 2015 and 2016–2017 respectively, and included
plasma viral load, CD4 cell count, and WHO staging.
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Adolescent interviews
At two study waves (0 and 18months follow-up), adoles-
cents completed tablet-based surveys in their preferred
language, with the support of research assistants trained
in working with South African adolescents. Surveys
assessed adolescents’ experiences at home, in their com-
munities, and in healthcare settings, and questions were
developed to be understandable and non-stigmatising
through extensive stakeholder consultation, including
with South African adolescents living with HIV [16, 17].
For the present analyses, self-reported data were only
used to determine participants’ sociodemographic
and treatment-related characteristics. Further study
information, including study protocol, is available at
www.mzantsiwakho.org.za.
Measures
Operational outcomes were evaluated in the HIV care
cascade between ART initiation and viral suppression
and included the following: availability of any clinical
records, having at least one viral load recorded within
clinical records, and having a viral load recorded within
the past 12 months (backdated from the date of extrac-
tion). Finally, viral suppression was measured at two
thresholds (HIV-1 RNA <1000 copies/mL and full viral
suppression designated at HIV-1 RNA <50 copies/mL)
[18]. Viral suppression was determined using the most
recent viral load available across records, including in
multiple facilities. Mortality was determined using both
clinical records and community tracing through May
2018. LTFU was defined as recorded in participants’
most recent clinical records, adjusted for mortality and
silent transfers into care at new facilities. Silent transfers
were identified when a patient re-entered care in a new
facility without an official notification to the former
facility of care. Participants without any available clinical
records were assumed to be LTFU.
In total, seven covariates were included in analyses [1]:
Age (younger adolescents aged 10–14 years vs. older ad-
olescents aged 15–19 years) [2]; sex [3]; residential loca-
tion at baseline (urban vs. rural) [4]; sexual vs. vertical
mode of infection (determined following existing sub-
Saharan African paediatric cohorts: age of ART initiation
cut-off [≤10 years] [19], validated and updated with a de-
tailed algorithm that considered other strong evidence
(i.e. self-reported sexual history and parental death) [20]
[5]; time on ART (≥2 vs. <2 years, measured from ART
initiation to date of viral load) [6]; experiencing decen-
tralised care (either exclusively at primary care clinics or
experienced down-referral from a higher- to lower-level
facility); and [7] mortality. For analyses of viral suppres-
sion, age at most recent viral load was binarized and
used as the age covariate (10–14 vs. 15–19 years). For
other outcomes, binarized age at study enrolment was
used (10–14 vs. 15–19 years). Mortality was included as
a covariate only for analyses of operational outcomes
(having a clinical record and having at least one viral
load in clinical records).
Statistical analysis
First, we summarised sociodemographic and treatment-
related characteristics of the cohort using descriptive
statistics. Second, we calculated the relevant proportion
of participants who had reached each step of the HIV
care cascade, including operational outcomes. The pro-
portion of participants with clinical records was mea-
sured out of the total study cohort, and the proportion
of participants with available viral loads was calculated
relative to participants with available clinical records.
The proportions of participants with viral loads recorded
in the past 12 months and viral suppression were calcu-
lated relative to the number of participants with at least
one recorded viral load.
Third, we tested associations between each step of the
HIV care cascade and socio-demographic and treatment-
related predictors, using a sequential multivariable logistic
regression approach following Hosmer and Lemeshow
[21]. All covariates were simultaneously included in the
first model and then removed sequentially: the second and
third models retained only variables significant at p <0.10
and p <0.05, respectively. For each cascade outcome, the
final model controlled for test multiplicity, using the
Benjamini-Hochberg step-up procedure to correct for
false discovery rate [22]. For all models, correlation matri-
ces indicated no multicollinearity between variables. All
possible two- and three-way interactive effects between
covariates significant in the final model were also tested
and corrected using the Benjamini-Hochberg procedure
and the Wald test for significance. Fourth, predicted prob-
abilities for covariates significant in the final model were
estimated by sex and mode of infection [23]. Multivariable
logistic regressions and marginal probability models were
performed using SPSS version 23 (IBM Corp, Armonk,
NY) and STATA/SE 15.1 (StataCorp, College Station,
TX), respectively.
Ethical approval
Ethical approval for this study was given by the Univer-
sity of Oxford (SSD/CUREC2/12–21), University of Cape
Town (CSSR 2013/4; 2017/3), Eastern Cape Depart-
ments of Health and Basic Education, and ethical review
boards of all participating healthcare facilities. At both
study waves, adolescent participants and their caregivers
provided voluntary, informed, and written consent for
participation, including interviews and access to adoles-
cents’ clinical records. Initial review of patient registers
in healthcare facilities was only used to identify eligible
participants, and further access to clinical records was
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obtained only after adolescents consented to study par-
ticipation. In cases of low literacy among adolescents or
caregivers, all information and consent procedures were
read aloud in the participant’s preferred language. There
were no financial incentives for study participation, but
all participants received a certificate of participation,
snacks, and a small gift pack including pencils and soap.
Adolescents who refused to participate were still given
snacks. To minimise risk of stigma, all potentially pub-
licly available materials, such as participation certificates
and general information pamphlets, referred to the study
as one about general adolescent health in South Africa.
Results
A total of 1080 ART-initiated adolescents were
recruited into the study. Years of ART initiation ranged
from 2000 to 2017, providing 6921 person-years of
study follow-up across participants. Median age at
study enrolment was 13 years (IQR: 11–16 years), and
55.3% of participants were female (Table 1). Most par-
ticipants were living in urban locations (76.7%) and ver-
tically infected (74.8%). In the total cohort, mortality
and corrected LTFU rates (including those without
clinical records) were 3.3% (n=36) and 16.9% (n=183),
respectively. Overall, 37.9% of all facility-designated
LTFU patients (n=95) were found to be misclassified:
7.4% (n=7) due to unrecorded mortality, and 30.5%
(n=29) from re-entry into care after silent transfer to
a new facility.
Of the total adolescent cohort, 88.1% (n=951) had at
least one clinical record available (Fig. 1). Attending
multiple care facilities was common, with 29.8% (n=283)
of participants having records from at least two facilities.
In total, 51.3% (n=488) experienced decentralised care.
Among those with clinical records, median age at
ART initiation was 9 years (IQR: 6–12 years), and
median follow-up time since ART initiation was 7.2
years (IQR: 4.7–9.8 years). At baseline on ART, the ma-
jority of adolescents were viraemic, with 72.1% report-
ing detectable viral loads (≥50 copies/mL) (Table 1). At
baseline, at least 19.0% were severely immunocom-
promised (CD4 <200 cells/mm [3]), and at least 22.3%
were either moderately or severely symptomatic (WHO
Clinical Stage III/IV).
Among those with clinical records, a further 92.3%
(n=878) had at least one viral load recorded within
their files (Fig. 1). Of those with any viral load data,
75.4% (n=662) and 51.1% (n=449) had their most
recent viral load recorded in the past 24 and 12
months, respectively. Median age at most recent viral
load was 14 years (IQR: 12–17 years). Approximately
equal proportions of adolescents had their most re-
cent viral load recorded at a hospital (39.0%, n=342)
and a primary care clinic (39.7%, n=349), with 21.3%
(n=187) recorded at a community health centre. At
most recent viral load, 74.1% (n=651) were on first-
line ART with an NNRTI backbone, and 19.2% (n=
169) were on second-line ART with a PI backbone. A
further 6.6% (n=58) were on an NRTI-only or un-
specified ARV regimen.











Age at study enrolment (yrs, median (IQR)) 13 (11–16)
Age at ART initiation (yrs, median (IQR))* 9 (6–12)
Mode of infection
Vertically infected (n,%) 808 (74.8%)
Sexually infected (n,%) 272 (25.2%)




Data not available 157 (14.5%)
Baseline viral load
<50 copies/mL 99 (9.2%)
51–999 copies/mL 401 (37.1%)
≥1000 copies/mL 378 (35.0%)
Data not available 202 (18.7%)
Baseline CD4 count
<200 cells/mm3 205 (19.0%)
200–349 cells/mm3 192 (17.8%)
≥350 cells/mm3 515 (47.7%)
Data not available 169 (15.6%)
Baseline WHO Clinical Stage
Stage I 283 (26.2%)
Stage II 167 (15.5%)
Stage III 212 (19.6%)
Stage IV 29 (2.7%)
Data not available 388 (35.9%)
Follow-up time
Study follow-up time since ART initiation
(yrs, median (IQR))*
7.2 (4.7–9.8)
ART: Antiretroviral therapy; IQR: Interquartile Range; LTFU: Lost to follow-up
* Median values calculated among participants with available clinical records
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At most recent viral load, 76.2% (n=669) of those with
viral load data were virally suppressed at <1000 copies/
mL, and 58.4% (n=513) were fully virally suppressed at <
50 copies/mL (Fig. 1). This rate corresponds to 47.5%
full viral suppression at most recent viral load for the
total adolescent cohort. Only 23.2% (n=251) of the total
cohort demonstrated full viral suppression within the
past 12 months.
In the final multivariable model, male (AOR 1.55
[95%CI 1.05–2.28], p=0.026) and sexually infected ado-
lescents (AOR 1.71 [95%CI 1.06–2.74], p=0.028) were
more likely to have an available clinical record (Table 2).
However, sexual infection (AOR 0.28 [95%CI 0.15–0.52],
p <0.001) and older age at study enrolment (AOR 0.32
[95%CI 0.16–0.62], p=0.001) were associated with lower
likelihood of having at least one recorded viral load.
Male (AOR 2.36 [95%CI 1.28–4.37], p=0.006) and
rural-living adolescents (AOR 2.13 [95%CI 1.07–4.27],
p=0.033) were more likely to have a viral load avail-
able in clinical records (Table 2).
Longer time on ART (AOR 3.42 [95%CI 2.14–
5.47], p <0.001) and experiencing decentralised care
(AOR 1.39 [95%CI 1.06–1.83], p=0.018) were associ-
ated with having a viral load recorded in the past 12
months (Table 2). Longer time on ART was also as-
sociated with viral suppression at <1000 copies/mL
(AOR 1.72 [95%CI 1.09–2.72], p=0.020). However,
adolescents who were older at most recent viral load
(AOR 0.54 [95%CI 0.39–0.75], p <0.001) and rural-
residing (AOR 0.66 [95%CI 0.46–0.93], p=0.019)
were less likely to be virally suppressed at this level.
Similarly, adolescents on ART for longer were more
likely to be fully virally suppressed at <50 copies/mL
(AOR 1.70 [95%CI 1.12–2.58], p=0.013), but adoles-
cents who were older at most recent viral load were less
likely to be fully virally suppressed (AOR 0.72 [95%CI
0.55–0.94], p=0.017). Full results for all model stages for
each cascade outcome are provided in Additional Files 1
and 2. No significant three-way interactions were found
between variables significant in the final models for any
outcome.
In the marginal probability model, the average effect
of decentralised HIV care on likelihood of having a viral
load in the past 12 months was greater for females than
males (AOR 2.39 [95%CI 1.29–4.43], Wald χ2=7.60, p=
0.006), and greater for sexually infected adolescents than
their vertically infected counterparts (AOR 3.48 [95%CI
1.04–11.65], Wald χ2=4.10, p=0.043) (Fig. 2).
Discussion
This study provides a comprehensive estimate of the
current reality of adolescent HIV care and progression
to viral suppression through the HIV care cascade in
South Africa’s public healthcare system, including oper-
ational outcomes. These results highlight not only the
low rate of past-year viral suppression among adoles-
cents but also the importance of timely viral load moni-
toring. To our knowledge, this is the first study to
Fig. 1 Adolescent HIV care cascade by mode of infection
Haghighat et al. BMC Infectious Diseases           (2021) 21:60 Page 5 of 9
evaluate both the timing and rate of viral suppression
for a large cohort of adolescents across facilities in a
sub-Saharan African public healthcare setting [4, 24].
By tracing participants in the community and across
all 52 public facilities, this HIV care cascade adjusted for
under-reported mortality and silent transfers in esti-
mates of LTFU. At 16.9%, this study suggests that the
true rate of LTFU is higher than previously reported for
vertically infected adolescents in sub-Saharan Africa.
This difference may result from this study’s inclusion of
adolescents sexually infected with HIV, a sub-population
previously found to be at higher risk for LTFU [5, 24].
This study found that roughly 38% of adolescents des-
ignated as LTFU by facilities were misclassified due to
under-reported mortality and silent transfers. The im-
portance of including silent transfers for accurately
assessing patient outcomes has been noted elsewhere,
particularly in settings like South Africa without univer-
sal unique patient identifiers [25]. The high rate of silent
transfer may reflect adolescents’ residential mobility; ad-
olescents’ actively self-specialising care services across
multiple sites; or the effect of decentralising HIV care,
through which patients’ care is distributed across health-
care levels [25, 26]. Therefore, facility-based approaches
to HIV care and treatment in South Africa must account
for adolescents’ mobility across sites.
Findings suggest that South African adolescent pro-
gression to the final “90” of viral suppression in the
UNAIDS 90–90-90 treatment goal remains low, at 47.5%
for ART-initiated adolescents aged 10–19 years. There-
fore, this study extends evidence on the adolescent HIV
care cascade in South Africa, beyond ART initiation
rates previously reported by Maskew and colleagues to
the next step of viral suppression, linked across








AOR (95% CI); p value
VL recorded in past
12months (n=449)
AOR (95% CI); p value
Most recent VL <1000
copies/mL (n=669)
AOR (95% CI); p value
Most recent VL <50
copies/mL (n=513)
AOR (95% CI); p value
Mortality – –
Rural living – 2.13 (1.07–4.27); 0.033 – 0.66 (0.46–0.93); 0.019 –
Sex (male) 1.55 (1.05–2.28);
0.026
2.36 (1.28–4.37); 0.006 – – –
Age at study enrolment
(≥15 years)
– 0.32 (0.16–0.62); 0.001 0.82 (0.62–1.10); 0.181
Sexually infected 1.71 (1.06–2.74);
0.028
0.28 (0.15–0.52); <0.0001 – – –
Decentralised care – 1.39 (1.06–1.83); 0.018 – –
Time on ART (≥2 years) 3.42 (2.14–5.47); <0.0001 1.72 (1.09–2.72); 0.020 1.70 (1.12–2.58); 0.013
Age at most recent VL
(≥15 years)
0.54 (0.39–0.75); <0.0001 0.72 (0.55–0.94); 0.017
AOR Adjusted odds ratio, ART Antiretroviral therapy, CI 95% Confidence interval, VL Viral load
Note: Adjusted odds ratios are only indicated for variables remaining in the final model for each outcome. Empty boxes indicate variables that were not
applicable to analyses. Boxes filled with a dash indicate variables not included in the final model because they had failed to reach significance in prior models
Fig. 2 Predicted probabilities of decentralised care by sex (left) and mode of infection (right) on recent viral load
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healthcare facilities [10]. This low rate of viral suppres-
sion in clinical records corroborates previously published
findings on ART adherence from this adolescent cohort,
which identified 49% self-reported past-week ART
adherence among adolescents at the study’s 18-month
follow-up interview [14]. Hence, findings suggest that
critical challenges persist in adolescent attainment of
consistent ART adherence and viral suppression after
treatment initiation.
Further, this study investigated the critical implemen-
tation question of the frequency of viral load testing.
This operational outcome reflects the extent to which
adolescent HIV care in South Africa’s decentralised
health system actually adheres to national guidelines.
National guidelines recommend at least annual viral load
testing for all adolescents, even in the most decentralised
community-based care models [11]. We found that only
half of adolescents with available viral loads had their
most recent viral load tested in the past 12 months. This
rate of adolescents’ viral load testing is far below the
provincial estimate of 80% of all ART-initiated patients
having a viral load within the past 12 months [27].
Although adolescents’ viral load availability may be high,
these results suggest that adolescents’ viral loads are
often out-dated. Because viral load monitoring is the pri-
mary approach for South African healthcare providers to
determine patients’ clinical care needs, the lack of recent
viral load data available in routine clinical records may
significantly reduce their ability to make appropriate
care decisions [11].
Only 23.2% of all adolescents were documented to be
virally suppressed in the past year. This low rate of past-
year viral suppression potentially provides a more mean-
ingful representation of the current state of adolescent
HIV care in South Africa. As younger adolescents age
and become sexually active and have children, routine
viral load monitoring and suppression become even
more crucial for prevention of onwards transmission to
partners and children [1]. While longer time on ART
and receiving decentralised care were associated with
having a viral load reported in the past 12 months, the
protective effect of decentralised care was stronger for
females and for sexually infected adolescents. These sub-
populations may be more likely to engage with decentra-
lised care through access to sexual and reproductive
health services at primary care clinics.
This study has several limitations. Because study eligi-
bility was limited to ART-initiated adolescents, findings
are not generalisable to rates of viral suppression for ad-
olescents living with HIV who have not been tested or
initiated on ART, in the first two steps of the UNAIDS
90–90-90 target and care cascade. However, this study’s
inclusion of adolescents who were LTFU or disengaged
from care minimised the risk of sample selection bias.
Because this retrospective cohort study analysed routine
clinical records, it is only able to present estimates based
on data that would be available to healthcare providers
in facilities. Rates of viral suppression presented in this
study represent the proportion of adolescents known
and documented to have achieved viral suppression.
Although adolescents without any electronic or paper-
based viral load records could potentially be virally sup-
pressed, this information was not available. In line with
previous studies, these adolescents were presumed to be
disengaged from care and thus likely to have unsup-
pressed viral loads [6, 28].
Additionally, the present study is unable to systematic-
ally identify precise reasons for out-dated or missing
viral loads for each participant. Potential factors include
both provider-related challenges (inconsistent record-
keeping systems resulting in missed scheduling, invalid
test results, or lost test results), and patient-related chal-
lenges (true disengagement from care, being unwilling
or unable to queue for blood tests, or having a proxy
pick up medications and report on their health) [29, 30].
Potential transfers to facilities beyond the health district
or into private care were not captured.
However, this study has several significant methodo-
logical strengths. Notably, participant tracing in the
community allowed for correction of facilities’ mortality
records. Tracing individual patients across 52 healthcare
facilities enabled a more accurate evaluation of adoles-
cents’ health by including unrecorded patient-initiated
silent transfers to new facilities [24, 25]. This improved
estimates for not only LTFU but also most recent viral
loads. Analysis of clinical records through December
2017 also allowed for evaluation of adolescent viral load
monitoring and HIV care outcomes in the era of univer-
sal test and treat. These outcomes reflect the current
reality of how ART-initiated adolescents are receiving
follow-up care and responding to treatment within a
healthcare system responsible for a larger patient popu-
lation than even before. Additionally, through linking
adolescents’ self-reported information to clinical records,
this cohort study was able to evaluate the effects of
individual-level predictors on progression along the HIV
care cascade, which has not been possible in previous
analyses of records from national databases [10, 24].
Finally, by evaluating adolescents’ clinical records across
52 public facilities in the Eastern Cape, findings poten-
tially represent outcomes for adolescents in similar set-
tings across South Africa and sub-Saharan Africa—
beyond findings from highly resourced and externally
supported clinics.
Further longitudinal analysis of outcomes is required
to investigate the cyclical nature of engagement with
HIV care, in order to identify when and which adoles-
cents disengage from the HIV care cascade [31]. Future
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research within this adolescent cohort should also exam-
ine self-reported clinical care experiences as predictors
of HIV care outcomes. Identifying reasons for gaps in
the operational outcomes from this HIV care cascade
and strategies to improve timely viral load monitoring
for adolescents is critical for effective programmatic and
policy changes.
Conclusions
This study documents progression of ART-initiated adoles-
cents across the HIV care cascade to viral suppression in a
sub-Saharan African public healthcare setting, accounting
for mortality and silent transfers. Adolescents living with
HIV in the Eastern Cape, South Africa, demonstrate low
rates of viral suppression, and viral load monitoring prac-
tices fall well below national guidelines. The effectiveness of
UNAIDS 90–90-90 goals for achieving HIV treatment suc-
cess requires not only viral suppression but also routine,
up-to-date viral load monitoring and recording.
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